Fipravirimat is an experimental drug for the treatment of
HIV/AIDS
Human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV), a retrovirus. Following initial infection an individual ...
. It belongs to a class of drugs known as
maturation inhibitors.
Fipravirimat is being developed by
ViiV Healthcare
ViiV Healthcare ( ) is a pharmaceutical company specializing in the development of therapies for HIV infection that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets ...
and as of 2023 is in
Phase II clinical trials
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...
.
See also
*
BMS-955176
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T ...
References
{{antiinfective-drug-stub
Antiviral drugs
Carboxylic acids
Organofluorides
Pentacyclic compounds
Sulfones